Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assertio Holdings, Inc. filings document formal disclosures for a Nasdaq-listed commercial pharmaceutical company, including material-event reports, annual meeting voting results, governance actions, and capital-structure matters. The record includes disclosures on common stock, convertible senior notes, tender-offer communications, and amendments to equity incentive plan provisions.
Assertio's SEC reports also cover material definitive agreements and completed asset-sale disclosures involving branded products such as INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP. These filings describe transaction documents, Regulation FD communications, shareholder approvals, executive-compensation plan matters, and operating subjects tied to the company's pharmaceutical commercialization business.
Assertio Holdings, Inc. reports its 2025 results and strategic refocus on oncology, led by ROLVEDON. Net product sales were $117.1 million in 2025 versus $120.8 million in 2024, with ROLVEDON contributing $68.2 million, reflecting its role as the lead product.
The company divested Assertio Therapeutics on May 9, 2025, transferring opioid‑related legal liabilities, and advanced integration of products under Assertio Specialty. Large distributor purchases in 2025 shifted ROLVEDON sales timing, with minimal net product sales expected in early 2026 before normalized volumes in the second quarter.
Assertio recorded a net loss from operations of $21.5 million and used $28.2 million of operating cash flow in 2025, ending the year with $63.4 million in cash, cash equivalents and short‑term investments. A 1‑for‑15 reverse stock split was effected on December 26, 2025, and the company highlights reliance on a few large distributors and single‑source manufacturers as key risks.
Assertio Holdings reported mixed 2025 results, with net product sales of $117.1 million slightly below 2024, but non-GAAP adjusted EBITDA improving to $22.7 million from $18.3 million. The company still posted a larger GAAP net loss of $30.4 million, versus $21.6 million a year earlier.
Rolvedon remained the main growth driver with full-year net product sales of $68.2 million, while Sympazan rose and Indocin declined under generic pressure. For 2026, Assertio guides to net product sales between $110 million and $125 million and adjusted EBITDA between $28 million and $40 million, reflecting expectations for stronger profitability despite ongoing portfolio transitions.
Schlessinger Sam reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings EVP and General Counsel Sam Schlessinger received new equity awards. On the reported date, he was granted 18,804 restricted stock units and 21,128 stock options, each RSU representing one share of common stock. One-third of both awards vest on each of the first three anniversaries of the grant date, subject to continued employment, and no cash consideration was paid for these grants.
Assertio Holdings, Inc. reported that EVP and CFO Ajay Patel acquired equity awards consisting of restricted stock units and stock options. He received 18,804 restricted stock units, each representing a right to receive one share of common stock, and 21,128 stock options.
One-third of both the restricted stock units and the stock options are scheduled to vest on each of the first three anniversaries of the March 2, 2026 grant date, assuming continued employment through each vesting date. The awards were granted for no cash consideration, so Patel did not pay to receive these derivative securities.
Assertio Holdings, Inc. reported that its President and COO, Paul Schwichtenberg, acquired equity awards in the form of restricted stock units and stock options. He received 24,820 restricted stock units, each representing a contingent right to one share of common stock, and 27,888 stock options. One-third of each award is scheduled to vest on each of the first three anniversaries of the March 2 grant date, contingent on continued employment. The awards were granted at no cost to him, as he did not pay any consideration for these derivative securities.
Reisenauer Mark L reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings CEO Mark L. Reisenauer received a grant of 26,667 stock options on March 2, 2026. These derivative securities were awarded at no cost to him and give the right to buy Assertio common stock.
One-third of the options will vest on each of the first three anniversaries of the grant date, assuming he remains employed through each vesting date. The reported amounts have been adjusted to reflect a 1-for-15 reverse stock split that occurred on December 26, 2025.
Assertio Holdings EVP and General Counsel Sam Schlessinger reported routine equity compensation activity. He exercised and settled 1,143 restricted stock units into the same number of common shares at $0.00 per share, then had 510 common shares withheld at $11.84 per share to cover taxes. After these transactions, he directly owned 14,738 shares of Assertio common stock.
Assertio Holdings EVP and CFO Ajay Patel reported equity award transactions involving restricted stock units and common stock. On February 21, 2026, 1,143 restricted stock units were converted into 1,143 shares of common stock at a stated price of $0.00 per share, reflecting settlement of vested units. In a related move, 566 shares of common stock were withheld at $11.84 per share to cover tax obligations upon vesting, leaving Patel with 15,942 shares of common stock held directly after these transactions. The restricted stock units were granted at no cost and vest in three equal installments on February 21 of 2024, 2025 and 2026, subject to continued employment.
Assertio Holdings, Inc. President and COO Paul Schwichtenberg reported equity compensation activity involving restricted stock units and common stock. He exercised 1,143 restricted stock units, which converted into 1,143 shares of common stock at a price of $0.0000 per share.
Of the resulting common shares, 566 were withheld at $11.8400 per share to cover tax obligations upon vesting, leaving him with 13,987 shares of common stock held directly after the transactions. Each restricted stock unit represents the right to receive one share of common stock.
The restricted stock units vest in three equal installments on February 21, 2024, February 21, 2025 and February 21, 2026, subject to continued employment. The derivative securities were granted to him without any purchase price being paid.
Assertio Holdings, Inc. executive vice president and general counsel Sam Schlessinger reported equity award activity involving restricted stock units and common stock. On February 18, 2026, he exercised 2,778 restricted stock units, which settled into 2,778 shares of common stock at no cash cost, reflecting the conversion of previously granted derivative securities.
In a related move, 1,239 common shares were withheld on the same date to cover tax obligations upon vesting, at a reported price of 11.8700 per share, characterized as a tax-withholding disposition rather than an open-market sale. Following these transactions, Schlessinger directly held 14,105 shares of common stock and 5,555 restricted stock units. The filing notes that each restricted stock unit represents the right to receive one share of common stock and that one-third of the reported units vests on each of February 18, 2026, 2027, and 2028, contingent on continued employment.